New data showcase reduction in disease activity by Uplizna in Immunoglobulin G4-Related Disease and support shorter infusion times for Krystexxa co-administered with weekly oral methotrexate 15 mg.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback